Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center, established in 1975, stands as a premier institution within the global healthcare and clinical research landscape. Headquartered in Seattle, Washington, the organization is dedicated to the prevention, diagnosis, and treatment of complex, life-threatening diseases, with a specialized focus on oncology, HIV/AIDS, and infectious disease research. By seamlessly integrating advanced clinical care with rigorous scientific inquiry, the center maintains a comprehensive portfolio of therapeutic innovations, vaccine development, and sophisticated data-driven medical modeling.

Currently operating across 15 distinct locations, Fred Hutchinson Cancer Center supports a diverse workforce of 5,000-10,000 employees who are deeply committed to next-generation oncology, immunology, and patient-centered care. The center’s expansive infrastructure facilitates high-impact clinical trials, state-of-the-art proton therapy, and specialized infusion services, ensuring superior patient outcomes and operational excellence. Their ongoing commitment to inclusive environments and robust educational programs further solidifies their status as a critical leader in medical innovation and public health advancement.

The institution maintains a competitive market position, operating alongside major research entities such as Memorial Sloan Kettering Cancer Center, City of Hope, and the Dana-Farber Cancer Institute. Through its extensive network of world-class scientists and medical professionals, the center continues to drive the commercialization of life-saving treatments and global disease eradication strategies. Meet Fred Hutchinson Cancer Center's team to learn more about the leadership, researchers, and clinical experts who are actively driving these critical medical advancements and shaping the future of healthcare.